Blood test may predict who suffers from radiation therapy
NCT ID NCT00893035
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a blood test measuring how certain immune cells die after radiation can predict long-term side effects in breast and prostate cancer patients. Researchers enrolled 885 participants and tracked late complications. The goal is to personalize treatment to reduce harm.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test that helps doctors personalize radiation doses to reduce long-term side effects.
- What could go wrong
- This is an observational study, not a treatment trial. The test may not prove accurate enough for routine use, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CRLC Val d'Aurelle
Montpellier, 34000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a new tracer light up hidden prostate cancer?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could deep breaths before surgery ward off Post-Op confusion?
- Could ionized gas help fight breast cancer after surgery?